Skip to main content
PALVELLA THERAPEUTICS, INC. logo

PALVELLA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · PVLA ISIN · US7207951036 LEI · 254900AJDH8PAOOI5T33 US Manufacturing
Filings indexed 748 across all filing types
Latest filing 2026-05-07 Regulatory Filings
Country US United States of America
Listing US PVLA

About PALVELLA THERAPEUTICS, INC.

https://palvellatx.com/

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for serious, rare genetic skin diseases (genodermatoses). The company's lead product candidate is QTORIN rapamycin, a novel, patented 3.9% rapamycin anhydrous gel. As a mammalian target of rapamycin (mTOR) inhibitor, QTORIN is designed to address skin diseases driven by the overactivation of the mTOR pathway. The candidate is in clinical development for conditions including microcystic lymphatic malformations (Phase 3) and cutaneous venous malformations (Phase 2).

Recent filings

Filing Released Lang Actions
8-K - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)
Regulatory Filings
2026-05-07 English
10-Q - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)
Quarterly Report
2026-05-07 English
8-K - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)
Regulatory Filings
2026-04-13 English
8-K - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)
Regulatory Filings
2026-04-07 English
10-K - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)
Annual Report FY 2025
2026-03-31 English
8-K - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)
Regulatory Filings
2026-03-31 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.